Olverembatinib

Buy Olverembatinib Tablets Online in India
Generic Name/API:Olverembatinib
Packaging:60 tablets per bottle
Storage:Store at 20°C to 25°C
Dosage:For dosage information, please check the General Information section.
Strength:30 mg and 40 mg
Indication:It is indicated for the treatment of adult patients with TKI-resistant chronic-phase Chronic Myeloid Leukemia (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation.

Olverembatinib is a BCR-ABL1 tyrosine kinase inhibitor , it was approved in China for the treatment of adult patients with TKI-resistant chronic-phase Chronic Myeloid Leukemia (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation.

STRENGTH:  

Olverembatinib is currently available in China in two tablet strengths: 30 mg and 40 mg. 

DOSAGE:

In the Phase I study published in the Journal of Hematology & Oncology, orally administered olverembatinib was evaluated at escalating alternate-day (QOD) doses ranging from 1 mg to 60 mg in 28-day treatment cycles.

ADVERSE EFFECTS:

Serious adverse events included thrombocytopenia, anemia, pneumonia, fever, and atrial fibrillation. 

Frequent nonhematologic treatment-related adverse events were changes in skin pigmentation and hypertriglyceridemia. Alterations in cutaneous pigmentation manifested as lentiginous nevi that did not require intervention or treatment discontinuation. The pathological mechanism has yet to be elucidated.

Potentially treatment-related cardiovascular events associated with olverembatinib included hypertension, pericardial effusion, ventricular extrasystoles, atrial fibrillation or supraventricular extrasystoles, retinal vein occlusion , and palpitations. Treatment-related angina, atrial tachycardia, cardiomegaly, arrhythmia, cerebral ischemia, and/or cerebral infarction were observed in <1% of patients each. 

STORAGE: 

  • 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light).
  1. Myelosuppression: The drug frequently causes severe hematologic toxicities, including decreased platelets (thrombocytopenia), neutropenia, and anemia. Regular complete blood counts (CBC) are required, and dose interruptions or reductions may be necessary.
  2. Cardiovascular Events: Although generally showing a lower incidence of severe vascular events than some other TKIs (like ponatinib), olverembatinib can cause hypertension and has been associated with rare but serious events like myocardial infarction. Cardiovascular risk factors should be tightly managed.
  3. Liver Enzyme Elevations: Asymptomatic elevations of liver transaminases and hyperbilirubinemia are common. Baseline and periodic liver function tests (LFTs) are necessary.
  4. Lipid and Metabolic Abnormalities: It can induce hypertriglyceridemia and hyperuricemia. Monitoring of lipid profiles and uric acid levels is advised to prevent metabolic and gout-related complications.
  5. Skin Pigmentation: The most common non-hematologic side effect is skin hyperpigmentation, which generally presents as harmless, tiny dark moles.
  6. Proteinuria: Mild to moderate proteinuria is frequently observed. Kidney function should be monitored throughout treatment.
  7. Pregnancy and Breastfeeding: Olverembatinib is contraindicated during pregnancy and breastfeeding, as it can cause fetal harm. Patients of childbearing potential should use effective contraception.

Import Olverembatinib in India through Named Patient Program

FAQ

Olverembatinib is a BCR-ABL1 tyrosine kinase inhibitor. Indicated for the treatment of adult patients with TKI-resistant chronic-phase Chronic Myeloid Leukemia (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation.

Unlike first- and second-generation TKIs, Olverembatinib has demonstrated strong activity against resistant mutations, including T315I, which is often associated with treatment failure.

Olverembatinib has been approved in China for specific leukemia indications, while global clinical development and regulatory evaluations are ongoing in several regions.

Common adverse effects may include:

  • Thrombocytopenia
  • Anemia
  • Hypertriglyceridemia
  • Skin pigmentation changes
  • Hypertension
  • Fever
  • Fatigue

The cost of Olverembatinib in India varies based on dosage, availability and import requirements. Contact 24/7QualityMeds at +91 9967979080 for current pricing details.

Yes, a valid prescription is generally required to buy Olverembatinib online in India and ensure safe, medically supervised treatment.

To buy Olverembatinib tablets in India, a valid prescription is generally required. Contact 24/7QualityMeds for availability, procurement and import assistance.

Related products